Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women

Clinical and Vaccine Immunology

Volumn 13, Issue 4, 2006, Pages 511-519

  Silverberg, Michael J ^a,h   Schneider, Michael F ^a   Silver, Barbara ^b   Anastos, Kathryn M ^c   Burk, Robert D ^d   Minkoff, Howard ^e   Palefsky, Joel ^f   Levine, Alexandra M ^g   Viscidi, Raphael P ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e MAIMONIDES MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CIGARETTE SMOKING; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; REINFECTION; SEROCONVERSION; SERODIAGNOSIS; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; VIRUS DETECTION; VIRUS GENOME; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REACTIVATION; VIRUS REPLICATION;

ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HIV; HIV ANTIBODIES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK FACTORS; VIRUS REPLICATION;

EID: 33745890612     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.13.4.511-519.2006     Document Type: Article

References (37)

1. af Geijersstam, V., M. Kibur, Z. Wang, P. Koskela, E. Pukkala, J. Schiller, M. Lehtinen, and J. Dillner. 1998. Stability over time of serum antibody levels to human papillomavirus type 16. J. Infect. Dis. 177:1710-1714.
2. Ahdieh, L., R. S. Klein, R. Burk, S. Cu-Uvin, P. Schuman, A. Duerr, M. Safaeian, J. Astemborski, R. Daniel, and K. Shah. 2001. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J. Infect. Dis. 184:682-690.
3. Ahmed, R., and C. A. Biron. 1999. Immunity to viruses, p. 1295-1334. In W. E. Paul (ed.), Fundamental immunology. Lippincott-Raven Publishers, Philadelphia, Pa.
4. Barkan, S. E., S. L. Melnick, S. Preston-Martin, K. Weber, L. A. Kalish, P. Miotti, M. Young, R. Greenblatt, H. Sacks, J. Feldman, et al. 1998. The Women's Interagency HIV Study. Epidemiology 9:117-125.
5. Bosch, F. X., A. Lorincz, N. Munoz, C. J. Meijer, and K. V. Shah. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-265.
6. Brown, D. R., M. L. Shew, B. Qadadri, N. Neptune, M. Vargas, W. Tu, B. E. Juliar, T. E. Breen, and J. D. Fortenberry. 2005. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Infect. Dis. 191:182-192.
7. Calvelli, T., T. N. Denny, H. Paxton, R. Gelman, and J. Kagan. 1993. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 14:702-715.
8. Carter, J. J., L. A. Koutsky, J. P. Hughes, S. K. Lee, J. Kuypers, N. Kiviat, and D. A. Galloway. 2000. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181:1911-1919.
9. Cox, D. R., and D. Oates. 1984. Analysis of survival data. Chapman and Hall, London, United Kingdom.
10. Diggle, P. J., K. Y. Liang, and S. L. Zeger. 1995. Analysis of longitudinal data. Oxford University Press, New York, N.Y.
11. Dillner, J. 1999. The serological response to papillomaviruses. Semin. Cancer Biol. 9:423-430.
12. Engels, E. A., D. E. Rollison, P. Hartge, D. Baris, J. R. Cerhan, R. K. Severson, W. Cozen, S. Davis, R. J. Biggar, J. J. Goedert, and R. P. Viscidi. 2005. Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int. J. Cancer 117:1013-1019.
13. Evander, M., K. Edlund, A. Gustafsson, M. Jonsson, R. Karlsson, E. Rylander, and G. Wadell. 1995. Human papillomavirus infection is transient in young women: a population-based cohort study. J. Infect. Dis. 171:1026-1030.
14. Furuta, Y., F. Ohtani, H. Aizawa, S. Fukuda, H. Kawabata, and T. Bergstrom. 2005. Varicella-zoster virus reactivation is an important cause of acute peripheral facial paralysis in children. Pediatr. Infect. Dis. J. 24:97-101.
15. Furuta, Y., F. Ohtani, H. Kawabata, S. Fukuda, and T. Bergstrom. 2000. High prevalence of varicella-zoster virus reactivation in herpes simplex virus-seronegative patients with acute peripheral facial palsy. Clin. Infect. Dis. 30:529-533.
16. Hammarlund, E., M. W. Lewis, S. G. Hansen, L. I. Strelow, J. A. Nelson, G. J. Sexton, J. M. Hanifin, and M. K. Slifka. 2003. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9:1131-1137.
17. Hankins, C., F. Coutlee, N. Lapointe, P. Simard, T. Tran, J. Samson, L. Hum, et al. 1999. Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Can. Med. Assoc. J. 160:185-191.
18. Hessol, N. A., M. Schneider, R. M. Greenblatt, M. Bacon, Y. Barranday, S. Holman, E. Robison, C. Williams, M. Cohen, and K. Weber. 2001. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am. J. Epidemiol. 154:563-573.
19. Hildesheim, A., M. H. Schiffman, P. E. Gravitt, A. G. Glass, C. E. Greer, T. Zhang, D. R. Scott, B. B. Rush, P. Lawler, M. E. Sherman, et al. 1994. Persistence of type-specific human papillomavirus infection among cytologically normal women. J. Infect. Dis. 169:235-240.
20. Hirsch, H. H., and J. Steiger. 2003. Polyomavirus BK. Lancet Infect. Dis. 3:611-623.
21. Ho, G. Y., R. Bierman, L. Beardsley, C. J. Chang, and R. D. Burk. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338:423-428.
22. Kirstein, L. M., R. M. Greenblatt, K. Anastos, A. Levine, A. L. French, H. Minkoff, S. Silver, and S. J. Gange. 2002. Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J. Acquir. Immune Defic. Syndr. 29:495-503.
23. Kurman, R. J., D. E. Henson, A. L. Herbst, K. L. Noller, M. H. Schiffman, et al. 1994. Interim guidelines for management of abnormal cervical cytology. JAMA 271:1866-1869.
24. Maurmann, S., L. Fricke, H. J. Wagner, P. Schlenke, H. Hennig, J. Steinhoff, and W. J. Jabs. 2003. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J. Clin. Microbiol. 41:5419-5428.
25. Palefsky, J. M., H. Minkoff, L. A. Kalish, A. Levine, H. S. Sacks, P. Garcia, M. Young, S. Melnick, P. Miotti, and R. Burk. 1999. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J. Natl. Cancer Inst. 91:226-236.
26. Silverberg, M. J., M. E. Gore, A. L. French, M. Gandhi, M. J. Glesby, A. Kovacs, T. E. Wilson, M. A. Young, and S. J. Gange. 2004. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin. Infect. Dis. 39:717-724.
27. Sloots, T. P., J. P. Kapeleris, I. M. Mackay, M. Batham, and P. L. Devine. 1996. Evaluation of a commercial enzyme-linked immunosorbent assay for detection of serum immunoglobulin G response to human herpesvirus 6. J. Clin. Microbiol. 34:675-679.
28. Strickler, H. D., R. D. Burk, M. Fazzari, K. Anastos, H. Minkoff, L. S. Massad, C. Hall, M. Bacon, A. M. Levine, D. H. Watts, M. J. Silverberg, X. Xue, N. F. Schlecht, S. Melnick, and J. M. Palefsky. 2005. Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. J. Natl. Cancer Inst. 97:577-586.
29. Sun, X. W., L. Kuhn, T. V. Ellerbrock, M. A. Chiasson, T. J. Bush, and T. C. Wright, Jr. 1997. Human papillomavirus infection in women infected with the human immunodeficiency virus. N. Engl. J. Med. 337:1343-1349.
30. U.S. Department of Health and Human Services. 29 October 2004. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [Online.] http://aidsinfo.nih.gov/guidelines.
31. Viscidi, R. P., L. Ahdieh-Grant, B. Clayman, K. Fox, L. S. Massad, S. Cu-Uvin, K. V. Shah, K. M. Anastos, K. E. Squires, A. Duerr, D. J. Jamieson, R. D. Burk, R. S. Klein, H. Minkoff, J. Palefsky, H. Strickler, P. Schuman, E. Piessens, and P. Miotti. 2003. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J. Infect. Dis. 187:194-205.
32. Viscidi, R. P., K. L. Kotloff, B. Clayman, K. Russ, S. Shapiro, and K. V. Shah. 1997. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin. Diagn. Lab. Immunol. 4:122-126.
33. Viscidi, R. P., D. E. Rollison, E. Viscidi, B. Clayman, E. Rubalcaba, R. Daniel, E. O. Major, and K. V. Shah. 2003. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin. Diagn. Lab. Immunol. 10:278-285.
34. Viscidi, R. P., M. Schiffman, A. Hildesheim, R. Herrero, P. E. Castle, M. C. Bratti, A. C. Rodriguez, M. E. Sherman, S. Wang, B. Clayman, and R. D. Burk. 2004. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol. Biomark. Prev. 13:324-327.
35. Viscidi, R. P., B. Snyder, S. Cu-Uvin, J. W. Hogan, B. Clayman, R. S. Klein, J. Sobel, and K. V. Shah. 2005. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol. Biomark. Prev. 14:283-288.
36. Wang, S. S., M. Schiffman, T. S. Shields, R. Herrero, A. Hildesheim, M. C. Bratti, M. E. Sherman, A. C. Rodriguez, P. E. Castle, J. Morales, M. Alfaro, T. Wright, S. Chen, B. Clayman, R. D. Burk, and R. P. Viscidi. 2003. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br. J. Cancer 89:1248-1254.
37. Woods, G. L., and J. A. Washington. 1995. The clinician and the microbiology laboratory, p. 169-199. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, Philadelphia, Pa.